LED Medical Diagnostics announced that it has signed an agreement with the BC Cancer Agency to form a collaborative relationship with Genome British Columbia to create and commercialize a progression-risk assessment test for oral cancer. The test is based on a quantifiable genetic phenomenon known as Loss of Heterozygosity.